-+ 0.00%
-+ 0.00%
-+ 0.00%
Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece
Share
Listen to the news

CHICAGO, July 13, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has entered into an agreement for the commercialization of its type-2 diabetes medication DIABIT-IS X (sitagliptin phosphate) in the Greek market, through a distribution and promotion partnership with Libytec Pharmaceutical S.A. ("Libytec").

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending